Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
9.265 USD | +2.49% | -11.42% | -34.95% |
01:24pm | Guggenheim Upgrades Amicus Therapeutics to Buy From Neutral With $13 Price Target | MT |
10/05 | UBS Trims Price Target on Amicus Therapeutics to $19 From $20, Keeps Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.95% | 2.68B | |
+29.81% | 48.16B | |
-1.11% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+10.23% | 25.59B | |
-22.95% | 18.96B | |
+8.24% | 12.92B | |
+28.92% | 12.03B | |
-2.17% | 11.77B |
- Stock Market
- Equities
- FOLD Stock
- News Amicus Therapeutics, Inc.
- Amicus Therapeutics Insider Sold Shares Worth $129,693, According to a Recent SEC Filing